Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
19.09.2017 15:00:00

Global Legal Cannabis Sales Projected to Grow

NEW YORK, September 19, 2017 /PRNewswire/ --

According to a research published by Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016. The market is forecast to grow at a CAGR of 21.1% between 2017 and 2024, while reaching a value of $63.5 billion in global sales in 2024. The legal cannabis market is witnessing robust growth in part thanks to the increasing legalization and decriminalization of cannabis across North America and Europe. The rising demand of cannabis for recreational use and medical use is a key factor driving the growth in sales in the industry. The report points out that due to the complex regulatory structure at state level and federal level, the full potential of the market is not yet realized. Global Payout, Inc. (OTC: GOHE), mCig, Inc. (OTC: MCIG), 22nd Century Group Inc. (NYSE: XXII), Easton Pharmaceuticals, Inc. (OTC: EAPH), AXIM Biotechnologies, Inc. (OTC: AXIM)

One major obstacle of the legal cannabis market is to raise money. Because of discrepancy between some states and federal laws the banks still refuse to open checking accounts and do not lend money for cannabis business. According to an article by Forbes debt and equity financing resources exist for the cannabis industry are becoming more available. Scott Jordan who works with entrepreneurs in the industry as director of business development for Colorado-based Dynamic Alternative Finance, explained, "We're seeing some lenders that are looking for higher yields and returns, venturing into this space," he said according to the article. "In terms of equity, we also are seeing some of the larger hedge funds and other family offices," getting involved in cannabis finance, Forbes reported.

Global Payout, Inc. (OTC: GOHE) announced breaking news yesterday that executive management members of its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC", the "Company") successfully represented the Company this past week at the 4th annual Cannabis World Congress & Business Exposition held in Los Angeles, CA.

The expo has become one of the most prominent cannabis-related conferences held in the U.S. and brings together exhibitors who feature the latest technologies, solutions, and resources for businesses operating within the cannabis industry. While in attendance at the expo, members of the Company's executive management team, including Vanessa Luna, COO, strategically utilized it as an opportunity to network with other key figures and business owners throughout the industry to effectively promote and represent the MTRAC brand.

"Representation at events such as this present such a unique and powerful opportunity to grow our presence and establish new partnerships within an industry that is incredibly tight-knit and yet growing at an unprecedented rate," said MTRAC COO, Vanessa Luna. "I am encouraged by the many different connections we established during this expo, and I am optimistic about the likelihood of a decent number of them possibly materializing into new partnerships for our company at some point in the near future," Ms. Luna further remarked.

mCig, Inc. (OTCQB: MCIG), a diversified holdings company servicing the legal Cannabis, Hemp, and CBD markets, is committed to being the leading distributor of technology, products, and services to fit the needs of a rapidly expanding industry. Recently, the company announced that it is concluding efforts to raise up to $3 million under a private placement to qualified accredited investors for the expansion of its operations. MCIG continues to expand its Merchant Services capabilities along with adding improved methods of purchasing cannabis and CBD products.

22nd Cetury Group Inc. (NYSE: XXII) recently announced that, research collaboration with North Carolina State University has yielded several new Very Low Nicotine (VLN) tobacco varieties that contain no foreign DNA and no trace of genetic modification. The new Very Low Nicotine varieties are ideally suited for use in the Company's X-22 smoking cessation product in development and will also form the basis of other unique 22nd Century VLN products.

Easton Pharmaceuticals, Inc. (OTC: EAPH) is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. On August 16, 2017, the company announced it has advanced $575,000 towards its acquired interest in 45 acres of a 135-acre fully owned parcel of land for the cultivation, production and sale of medical / recreational marijuana to the cannabis industry and towards other revenue producing businesses. Pursuant to the agreement, Easton Pharmaceuticals has thus far paid $575,000 CDN of $1.3 million CDN to Toronto based Alliance Group to acquire an interest in 45 acres of agriculturally zoned land north of Toronto, Ontario, Canada to cultivate, produce and facilitate the sale of its production of medical marijuana and other lucrative revenue producing businesses on a co-managed basis. Alliance has already initiated the process to legally grow medical / recreational marijuana which it anticipates receiving and conveying positive news on within the next 30 to 60 days.

AXIM Biotechnologies, Inc. (OTCQB: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. On May 2, the company announced that the company's product development partner Quay Pharmaceuticals Ltd. has obtained the relevant licenses from the British Home Office to import and work with the controlled drugs that are required to continue the development of AXIM's MedChew Rx® pharmaceutical chewing gum's family of products. To develop and produce the MedChew Rx® family of chewing gums, AXIM Biotech works with its partners to procure cannabis strains, extract and purify the strains into pharmaceutical-grade cannabinoids, develop and produce the cannabinoid-containing chewing gum products and afterwards undertake clinical trials.

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, FinancialBuzz.com has been compensated three thousand seven hundred fifty dollars for financial news dissemination and pr services by a non-affiliate third party for global payout, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com.

For further information:
info@financialbuzz.com
+1-877-601-1879


Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com

Nachrichten zu AXIM Biotechnologies Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu AXIM Biotechnologies Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!